Acumen Pharmaceuticals, Inc.
ABOSNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$123.8M | −$114.0M | −$61.1M | −$45.2M | −$19.6M | −$7.9M |
| Net income | −$121.3M | −$102.3M | −$52.4M | −$42.9M | −$100.6M | −$7.3M |
| Total assets | $122.8M | $239.0M | $310.1M | $196.6M | $230.3M | $44.4M |
| Total liabilities | $52.4M | $57.2M | $43.2M | $7.8M | $5.1M | $6.4M |
| Equity | $70.4M | $181.8M | $267.0M | $188.8M | $225.2M | −$18.6M |
| EPS (diluted) | $-2.00 | $-1.71 | $-1.08 | $-1.06 | $-5.02 | — |
| Shares out. | 60.6M | 60.1M | 41.0M | 40.5M | 40.5M | 419,124 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −172.3%
- Return on assets
- −98.8%
- Return on capital (ROCE)
- −133.4%
- Liabilities / assets
- 42.7%
- Debt / equity
- 0.74×
- Book value / share
- $1.16
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -12.29distress
- Accruals / assets
- −4.7%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Murray James B JrPassive (13G)Apr 7, 2026
- Ra Capital Management, L.P.Activist (13D)Mar 17, 2026
- Franklin Resources IncPassive (13G)Nov 4, 2025
- Sands Capital Alternatives, LlcPassive (13G)Aug 13, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.7M | 6.4 | +4.3% |
| Apr 30, 2026 | 1.7M | 5.2 | +8.5% |
| Apr 15, 2026 | 1.5M | 3.1 | +46.4% |
| Mar 31, 2026 | 1.1M | 1.0 | +2.3% |
| Mar 13, 2026 | 1.0M | 3.1 | +7.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 12, 2026
- Results of operations · Regulation FD disclosureMar 26, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureMar 16, 2026
- Regulation FD disclosureJan 12, 2026
- Results of operations · Regulation FD disclosureNov 12, 2025
- Director / officer change · Regulation FD disclosureNov 10, 2025
- Results of operations · Regulation FD disclosureAug 12, 2025
- Entered a material agreement · Regulation FD disclosureJul 15, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.